Anna Orlova at Uppsala University - Research Interests, Publications & Academic Profile

Anna Orlova

Uppsala University

Sweden

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Chinese students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Medical Imaging

40%

Pharmacology

70%

Radiopharmaceutical Chemistry

60%

Pet Imaging

40%

Preclinical Imaging

40%

Molecular Imaging

40%

G Protein-coupled Receptor

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles11

Two Novel [68Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar11]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer

Article Link

Year:

2024

Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors

Article Link

Year:

2023

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model

Article Link

Year:

2023

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [68Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation

Article Link

Year:

2023

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics

Article Link

Year:

2023

Synthesis, 123I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures

Article Link

Year:

2023

The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity

Article Link

Year:

2023

Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab

Article Link

Year:

2023

Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy

Article Link

Year:

2022

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis

Article Link

Year:

2022

The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer

Article Link

Year:

2022

Collaborators5

Sophia Hober

KTH Royal Institute of Technology

SWEDEN

Vladimir Tolmachev

Uppsala University

SWEDEN

Ulrika Rosenström

Uppsala Universitet Farmaceutiska fakulteten

SWEDEN

Anzhelika Vorobyeva

Uppsala University

SWEDEN

Sara Sophie Rinne

Weill Cornell Medicine

UNITED STATES

How do Chinese students reach out?

Meet Kite AI

Anna Orlova

How do Chinese students reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Articles11

Two Novel [<sup>68</sup>Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar<sup>11</sup>]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer

Phase I Trial of [<sup>99m</sup>Tc]Tc-maSSS-PEG<sub>2</sub>-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [68Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics

Synthesis, <sup>123</sup>I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures

The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity

Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab

Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis

The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer

Collaborators5

Sophia Hober

Vladimir Tolmachev

Ulrika Rosenström

Anzhelika Vorobyeva

Sara Sophie Rinne

How do Chinese students reach out?